EVIDENCE LIBRARY
Canadian Assisted-Dying Cohort Documents Midazolam Within a Multidrug Clinical Context
A retrospective Canadian study frequently recorded midazolam alongside other medications. Its results describe a specialized clinical setting and cannot isolate the causal contribution of midazolam to an individual death.
A retrospective Canadian study frequently recorded midazolam alongside other medications. Its results describe a specialized clinical setting and cannot isolate the causal contribution of midazolam to an individual death.
The setting behind the drug record
Stukalin and colleagues analyzed records for 3,557 adults receiving medical assistance in dying in Ontario and Vancouver. The data combined a provincial reporting database and chart reviews from three academic hospitals over different periods. Most patients had cancer.
Midazolam appeared in 3,251 records, or 91.4%. Propofol and rocuronium were also frequently recorded. Those overlapping proportions show why the medication context matters: the study did not observe isolated midazolam exposure in a typical poisoning population.
Association within a selected population
The investigators examined relationships between medication use, timing, and reported complications. Their retrospective design allowed description of practice and adjusted associations, but did not randomize the medications or remove clinical selection of particular regimens.
The limitations expressly recognize residual confounding. Patients’ cardiopulmonary reserve, medication tolerance, and clinicians’ decisions could influence both the medications chosen and observed outcomes. Adjustment for recorded variables cannot reconstruct everything that guided care.
Implications for forensic interpretation
A benzodiazepine in a death record may reflect documented medical administration. Establish the chronology and purpose of treatment before interpreting detection as evidence of a preceding intoxication. This cohort offers evidence about treatment context, not a concentration-based rule for attributing death to midazolam.
The findings also should not be generalized to unattended deaths, routine procedural sedation, or accidental overdose without explaining the substantial population and co-medication differences. The paper is a descriptive clinical study, not a current statement of legal requirements.
Source
Based on the supplied paper: Medications and dosages used in medical assistance in dying a cross sectional study. PMC8920593.